ArticleJournal of neuro-oncology2026
Single-fraction Gamma Knife radiosurgery for pineal region meningiomas: a retrospective single-center cohort of 44 patients.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the long-term efficacy and safety of single-fraction Gamma Knife radiosurgery (GKRS) for pineal region meningiomas (PMs) and to clarify its role as both a primary and adjuvant treatment strategy for this anatomically challenging tumor location.
methodsThis single-center retrospective cohort study included 44 consecutive adults with PMs treated with single-fraction GKRS. Diagnosis was established histopathologically after prior surgery or by predefined MRI criteria with consensus neuroradiological review. Tumor response was assessed volumetrically on serial contrast-enhanced MRI, with regression, stability, and progression defined as ≥ 20% decrease, < 20% change, and ≥ 20% increase in tumor volume, respectively. Local control (LC), progression-free survival (PFS), overall survival (OS), adverse radiation effects (AREs), and Karnofsky Performance Scale (KPS) outcomes were analyzed.
resultsMedian clinical and radiological follow-up were 90 and 88 months, respectively. At last radiological follow-up, LC was achieved in 42 of 44 patients (95.5%), including regression in 13 (29.5%) and stability in 29 (65.9%). Kaplan-Meier LC rates were 100% at 2 years, 97.1% at 5 years, and 86.3% at 10 years. PFS rates were 100%, 94.1%, and 72.6% at 2, 5, and 10 years, respectively. AREs occurred in 3 patients (6.8%), all without permanent sequelae. KPS remained stable or improved in all patients.
conclusionSingle-fraction GKRS provides durable tumor control with low toxicity and preserved neurological function in PMs, supporting its use as a primary treatment strategy in selected patients. Preliminary adjuvant results are encouraging but require validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.